Patents by Inventor Hermann Wehlmann

Hermann Wehlmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10683508
    Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 16, 2020
    Assignee: BAYER ANIMAL HEALTH GMBH
    Inventors: Marc Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
  • Patent number: 10155950
    Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: December 18, 2018
    Assignee: Bayer Animal Health GmbH
    Inventors: Marc Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
  • Publication number: 20180312842
    Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.
    Type: Application
    Filed: April 25, 2018
    Publication date: November 1, 2018
    Inventors: Marcus Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
  • Patent number: 9719064
    Abstract: The present invention describes the DNA-sequence of the wild type genome as well as all genetic modifications which were introduced into the wild type—and further developed strains, based thereon. Thereby the first genotypic characterization of the developed strains, including the latest production strain, has been accomplished, accounting for the major part of the invention. Furthermore, on the basis of the determined DNA-sequences, potential genes were identified and account, combined with their functional annotation, for another part of the invention. In particular, the gene- and DNA-sequences, as well as protein-sequences derived there out, contribute to the invention which were affected by mutagenic modifications throughout the strain development process, potentially contributing to the increased production yield.
    Type: Grant
    Filed: August 1, 2011
    Date of Patent: August 1, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Klaus Selber, Bernhard Weingaertner, Hermann Wehlmann, Winfried Rosen, Alfred Pühler, Patrick Schwientek, Jörn Kalinowski, Udo Wehmeier
  • Patent number: 9562249
    Abstract: The present invention is directed to an innate DNA sequence within the complete genome sequence of Actinoplanes sp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found in Actinoplanes sp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AICEs from other species.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: February 7, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Andreas Klein, Klaus Selber, Hermann Wehlmann, Winfried Rosen, Alfred Pühler, Patrick Schwientek, Jörn Kalinowski, Udo Wehmeier
  • Publication number: 20160130622
    Abstract: The present invention is directed to an innate DNA sequence within the complete genome sequence of Actinoplanes sp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found in Actinoplanes sp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AICEs from other species.
    Type: Application
    Filed: November 12, 2015
    Publication date: May 12, 2016
    Inventors: Andreas KLEIN, Klaus SELBER, Hermann WEHLMANN, Winfried ROSEN, Alfred PÜHLER, Patrick SCHWIENTEK, Jörn KALINOWSKI, Udo WEHMEIER
  • Patent number: 9217154
    Abstract: The present invention is directed to an innate DNA sequence within the complete genome sequence of Actinoplanes sp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found in Actinoplanes sp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AiCEs from other species.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: December 22, 2015
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Andreas Klein, Klaus Selber, Hermann Wehlmann, Winfried Rosen, Alfred Pühler, Patrick Schwientek, Jörn Kalinowski, Udo Wehmeier
  • Publication number: 20150267201
    Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.
    Type: Application
    Filed: February 27, 2015
    Publication date: September 24, 2015
    Applicant: BAYER ANIMAL HEALTH GMBH
    Inventors: Marc Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
  • Publication number: 20140349346
    Abstract: The present invention is directed to an innate DNA sequence within the complete genome sequence of Actinoplanes sp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found in Actinoplanes sp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AiCEs from other species.
    Type: Application
    Filed: December 4, 2012
    Publication date: November 27, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Andreas Klein, Klaus Selber, Hermann Wehlmann, Winfried Rosen, Alfred Pühler, Patrick Schwientek, Jörn Kalinowski, Udo Wehmeier
  • Publication number: 20130302855
    Abstract: The present invention describes the DNA-sequence of the wild type genome as well as all genetic modifications which were introduced into the wild type-and further developed strains, based thereon. Thereby the first genotypic characterization of the developed strains, including the latest production strain, has been accomplished, accounting for the major part of the invention. Furthermore, on the basis of the determined DNA-sequences, potential genes were identified and account, combined with their functional annotation, for another part of the invention. In particular, the gene-and DNA-sequences, as well as protein-sequences derived there out, contribute to the invention which were affected by mutagenic modifications throughout the strain development process, potentially contributing to the increased production yield.
    Type: Application
    Filed: August 1, 2011
    Publication date: November 14, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Klaus Selber, Bernhard Weingaertner, Hermann Wehlmann, Winfried Rosen, Alfred Puhler, Patrick Schwientek, Jörn Kalinowski, Udo Wehmeier
  • Patent number: 6506590
    Abstract: The present invention relates to the construction and use of expression plasmids in the manufacture of recombinant interleukin-4 (IL-4) and interleukin-4 muteins.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: January 14, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Heiner Apeler, Hermann Wehlmann
  • Patent number: 6130318
    Abstract: The present invention relates to novel hIL-4 mutant proteins, to processes for preparing them, and to their use as medicaments, in particular in overshooting, falsely regulated immune reactions and autoimmune diseases.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: October 10, 2000
    Assignee: Bayer Aktiengellschaft
    Inventors: Hanno Wild, Rudolf Hanko, Michael Dorschug, Hans-Dietrich Horlein, Jurgen Beunink, Heiner Apeler, Hermann Wehlmann, Walter Sebald